Tyrosine kinase and HIF-2α inhibitors have been proposed for treatment of pseudohypoxic PCPG61, therefore, a similar rationale may be extended to C2B2 (MAML3) tumors, which have a higher propensity to develop metastatic disease. Here, EPAS1 is linked to metastatic neoplasm.